NFE2L2 and metabolic dysfunction-associated steatotic liver disease: Swertiamarin can attenuate liver injury in nonalcoholic fatty liver disease mice through the pathway of up-regulation of the Nrf2/HO-1 pathway and down-regulation of reactive oxygen species binding protein-1 [44].